Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I would like to welcome everyone to the Theravance Biopharma Third Quarter 2024 Conference Call.
Theravance Biopharma Inc. (TBPH)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 9,511,150 | $76,659,869 | +12% | 7.1% |
| 2. | Weiss Asset Management Andrew Weiss | 7,457,060 | $60,103,904 | 1.38% | |
| 3. | Newtyn Management Noah Levy And Eugene Dozortsev | 4,499,066 | $36,262,472 | +112% | 5.56% |
| 4. | Irenic Capital Management Adam Katz And Andy Dodge | 2,760,948 | $22,253,241 | 1.95% | |
| 5. | Park West Asset Management Peter S. Park | 1,862,988 | $15,015,683 | +10% | 1.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 999,800 | Large Shareholder | 9,511,150 | 2024-08-07 | Filing | |
| $8.75 | 499,324 | Large Shareholder | 8,511,350 | 2024-05-01 | Filing | |
| $8.75 | 999,800 | Large Shareholder | 8,012,026 | 2024-05-01 | Filing | |
| $22.54 | 1,000 | Director | 56,757 | 2018-05-21 | Filing | |
| $26.34 | 4,000 | Officer | 213,180 | 2017-08-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.00 | 4,000 | 322,743 | 2024-11-11 | Filing | ||
| $9.00 | 4,000 | 335,965 | 2024-07-10 | Filing | ||
| $8.71 | 1,254 | 311,733 | 2024-02-22 | Filing | ||
| $10.29 | 1,378 | 331,206 | 2023-11-21 | Filing | ||
| $10.22 | 2,482 | 346,839 | 2023-11-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,587,834 | $51,567,256 | 0% | |
| 2. | 3,489,262 | $39,219,305 | 0% | |
| 3. | 2,168,397 | $24,372,782 | 0.02% | |
| 4. | 1,390,314 | $15,627,129 | 0% | |
| 5. | 994,000 | $11,173,535 | 0% |
News See All
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript August 5, 2024Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04.
Billionaire Seth Klarman’s Biotech Stock Picks
In this article, we discuss billionaire Seth Klarman’s biotech stock picks.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to Theravance Biopharma's Third Quarter 2023 Conference Call.
12 High Growth Value Stocks to Buy According to Seth Klarman
In this article, we will take a look at the 12 high growth value stocks to buy according to Seth Klarman.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to Theravance Biopharma's Second Quarter 2023 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I’d like to welcome everyone to the Theravance Biopharma First Quarter 2023 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Fourth Quarter and Full Year 2022 Conference Call. .